Simcock, Richard
Brighton and Sussex University Hospitals NHS Trust
3 papers on CoChatORCID 0000-0002-9828-4114
Most cited papers
- Verified
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 177
- Verified
Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer
Burcombe, R., Chan, S., Simcock, R., Samanta, K., Percival, F., & Barrett-Lee, P. (2013) · Advances in Breast Cancer Research
Health Systems, Economic Evaluations, Quality of LifeHER2/EGFR in Cancer Research
Cited by 59
- Verified
Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits
Fallowfield, L. J., Catt, S. L., May, S. F., Matthews, L., Shilling, V. M., Simcock, R., Westwell, S., & Jenkins, V. A. (2017) · Supportive Care in Cancer
Patient-Provider Communication in HealthcarePalliative Care and End-of-Life Issues
Cited by 25
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free